1 Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
- チオールプロテアーゼの阻害作用をもつ
- ＨＭＷ−キニノーゲンは血液の凝固においてプレカリクレインと第11因子を第12因子に引き続き活性化させる。
- トロンビンとプラスミンにより誘導される血小板の凝集を阻害する
- HMW-キニノーゲンから遊離するブラジキニンは多くの生理学的作用を示す（平滑筋収縮に影響、低血圧、ナトリウム利尿、血糖低下
- LMW-キニノーゲンは血小板の凝集を阻害する
- LMW-キニノーゲンは血液凝固に関与しない
